Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management

Valent, 2018, Mast cell activation syndrome: importance of consensus criteria and call for research, J Allergy Clin Immunol, 142, 1008, 10.1016/j.jaci.2018.06.004 Akin, 2014, Diagnostic criteria and classification of mastocytosis in 2014, Immunol Allergy Clin North Am, 34, 207, 10.1016/j.iac.2014.02.003 Cardet, 2013, Immunology and clinical manifestations of non-clonal mast cell activation syndrome, Curr Allergy Asthma Rep, 13, 10, 10.1007/s11882-012-0326-8 Metcalfe, 2001, Mastocytosis: molecular mechanisms and clinical disease heterogeneity, Leuk Res, 25, 577, 10.1016/S0145-2126(01)00046-7 Hartmann, 2016, Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology, J Allergy Clin Immunol, 137, 35, 10.1016/j.jaci.2015.08.034 Bodemer, 2010, Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations, J Invest Dermatol, 130, 804, 10.1038/jid.2009.281 Castells, 2011, Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations, Am J Clin Dermatol, 12, 259, 10.2165/11588890-000000000-00000 Valent, 2007, Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria, Eur J Clin Invest, 37, 435, 10.1111/j.1365-2362.2007.01807.x Bonadonna, 2009, How much specific is the association between hymenoptera venom allergy and mastocytosis?, Allergy, 64, 1379, 10.1111/j.1398-9995.2009.02108.x Alvarez-Twose, 2016, Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis, J Allergy Clin Immunol, 137, 168, 10.1016/j.jaci.2015.05.008 Alvarez-Twose, 2012, Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis, J Clin Oncol, 30, e126, 10.1200/JCO.2011.38.9973 Arock, 2015, KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis, Leukemia, 29, 1223, 10.1038/leu.2015.24 Hamilton, 2011, Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations, J Allergy Clin Immunol, 128, 147, 10.1016/j.jaci.2011.04.037 Akin, 2010, Mast cell activation syndrome: proposed diagnostic criteria, J Allergy Clin Immunol, 126, 1099, 10.1016/j.jaci.2010.08.035 Lyons, 2014, Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities, J Allergy Clin Immunol, 133, 1471, 10.1016/j.jaci.2013.11.039 Irani, 1986, Two types of human mast cells that have distinct neutral protease compositions, Proc Natl Acad Sci USA, 83, 4464, 10.1073/pnas.83.12.4464 Weidner, 1993, Heterogeneity of mast cells at multiple body sites. Fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content, Pathol Res Pract, 189, 156, 10.1016/S0344-0338(11)80086-5 Dwyer, 2016, Expression profiling of constitutive mast cells reveals a unique identity within the immune system, Nat Immunol, 17, 878, 10.1038/ni.3445 Castells, 2002, Mastocytosis: mediator-related signs and symptoms, Int Arch Allergy Immunol, 127, 147, 10.1159/000048188 Teodosio, 2010, Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes, J Allergy Clin Immunol, 125, 719, 10.1016/j.jaci.2009.10.020 Dale, 1910, The physiological action of beta-iminazolylethylamine, J Physiol, 41, 318, 10.1113/jphysiol.1910.sp001406 Borriello, 2017, Histamine release from mast cells and basophils, Handb Exp Pharmacol, 241, 121, 10.1007/164_2017_18 Schubert, 2017, Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion, Curr Opin Gastroenterol, 33, 430, 10.1097/MOG.0000000000000392 Friedman, 1989, Analysis of plasma histamine levels in patients with mast cell disorders, Am J Med, 87, 649, 10.1016/S0002-9343(89)80398-5 Keyzer, 1983, Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites, N Engl J Med, 309, 1603, 10.1056/NEJM198312293092603 Green, 1987, Aspects of histamine metabolism, Agents Actions, 22, 1, 10.1007/BF01968810 Maintz, 2007, Histamine and histamine intolerance, Am J Clin Nutr, 85, 1185, 10.1093/ajcn/85.5.1185 Divekar, 2015, Urinary 11beta-PGF2alpha and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders, Allergy, 70, 1230, 10.1111/all.12668 Ravi, 2014, Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11beta-prostaglandin2alpha, J Allergy Clin Immunol Pract, 2, 775, 10.1016/j.jaip.2014.06.011 Castells, 1987, Evaluation of human peripheral blood leukocytes for mast cell tryptase, J Immunol, 138, 2184, 10.4049/jimmunol.138.7.2184 Schwartz, 1986, Regulation of tryptase from human lung mast cells by heparin. Stabilization of the active tetramer, J Biol Chem, 261, 7372, 10.1016/S0021-9258(17)38401-6 Schwartz, 1989, Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis, J Clin Invest, 83, 1551, 10.1172/JCI114051 Valent, 2012, Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal, Int Arch Allergy Immunol, 157, 215, 10.1159/000328760 Schwartz, 2006, Diagnostic value of tryptase in anaphylaxis and mastocytosis, Immunol Allergy Clin North Am, 26, 451, 10.1016/j.iac.2006.05.010 Sahiner, 2014, Serum basal tryptase levels in healthy children: correlation between age and gender, Allergy Asthma Proc, 35, 404, 10.2500/aap.2014.35.3769 Belhocine, 2011, Total serum tryptase levels are higher in young infants, Pediatr Allergy Immunol, 22, 600, 10.1111/j.1399-3038.2011.01166.x Aberer, 2015, Disease spectrum in patients with elevated serum tryptase levels, Australas J Dermatol, 56, 7, 10.1111/ajd.12146 Fellinger, 2014, Clinical characteristics and risk profile of patients with elevated baseline serum tryptase, Allergol Immunopathol (Madr), 42, 544, 10.1016/j.aller.2014.05.002 Sabato, 2014, Familial hypertryptasemia with associated mast cell activation syndrome, J Allergy Clin Immunol, 134, 1448, 10.1016/j.jaci.2014.06.007 Lyons, 2016, Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number, Nat Genet, 48, 1564, 10.1038/ng.3696 Pugliese, 1985, Hepatic transformation of prostaglandin D2 to a new prostanoid, 9 alpha,11 beta-prostaglandin F2, that inhibits platelet aggregation and constricts blood vessels, J Biol Chem, 260, 14621, 10.1016/S0021-9258(17)38613-1 Crawhall, 1987, Systemic mastocytosis: management of an unusual case with histamine (H1 and H2) antagonists and cyclooxygenase inhibition, Clin Invest Med, 10, 1 Kootte, 1983, The flush syndrome: an expression of systemic mastocytosis with increased prostaglandin D2 production, Neth J Med, 26, 18 Roberts, 1984, Recurrent syncope due to systemic mastocytosis, Hypertension, 6, 285, 10.1161/01.HYP.6.2.285 Lorcerie, 1989, Aspirin and systemic mastocytosis, Lancet, 2, 1155, 10.1016/S0140-6736(89)91516-X Butterfield, 2009, Survey of aspirin administration in systemic mastocytosis, Prostaglandins Other Lipid Mediat, 88, 122, 10.1016/j.prostaglandins.2009.01.001 Butterfield, 2008, Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production, Int Arch Allergy Immunol, 147, 338, 10.1159/000144042 Butterfield, 1995, Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization, Mayo Clin Proc, 70, 481, 10.4065/70.5.481 Kumlin, 1997, Measurements of leukotrienes in the urine: strategies and applications, Allergy, 52, 124, 10.1111/j.1398-9995.1997.tb00966.x Kumlin, 1995, Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans, Clin Exp Allergy, 25, 467, 10.1111/j.1365-2222.1995.tb01079.x Lueke, 2016, Analytical and clinical validation of an LC-MS/MS method for urine leukotriene E4: a marker of systemic mastocytosis, Clin Biochem, 49, 979, 10.1016/j.clinbiochem.2016.02.007 Sala, 2010, Transcellular biosynthesis of eicosanoids, Pharmacol Rep, 62, 503, 10.1016/S1734-1140(10)70306-6 Denzlinger, 1995, Cysteinyl leukotriene production in anaphylactic reactions, Int Arch Allergy Immunol, 108, 158, 10.1159/000237133 Butterfield, 2010, Increased leukotriene E4 excretion in systemic mastocytosis, Prostaglandins Other Lipid Mediat, 92, 73, 10.1016/j.prostaglandins.2010.03.003 Theoharides, 2002, Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients, Int Arch Allergy Immunol, 128, 344, 10.1159/000063858 Brockow, 2005, IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis, Clin Immunol, 115, 216, 10.1016/j.clim.2005.01.011 Mayado, 2016, Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression, Leukemia, 30, 124, 10.1038/leu.2015.176 Yu, 2014, Differential effects of the Toll-like receptor 2 agonists, PGN and Pam3CSK4 on anti-IgE induced human mast cell activation, PLoS One, 9, e112989, 10.1371/journal.pone.0112989 Hoffmann, 2013, Inhibitory effects of benzodiazepines on the adenosine A(2B) receptor mediated secretion of interleukin-8 in human mast cells, Eur J Pharmacol, 700, 152, 10.1016/j.ejphar.2012.12.003 Rocha-de-Souza, 2008, Human mast cell activation by Staphylococcus aureus: interleukin-8 and tumor necrosis factor alpha release and the role of Toll-like receptor 2 and CD48 molecules, Infect Immun, 76, 4489, 10.1128/IAI.00270-08 Lappalainen, 2011, OxLDL-IgG immune complexes induce expression and secretion of proatherogenic cytokines by cultured human mast cells, Atherosclerosis, 214, 357, 10.1016/j.atherosclerosis.2010.11.024 Mulloy, 2017, Mast cell glycosaminoglycans, Glycoconj J, 34, 351, 10.1007/s10719-016-9749-0 Vysniauskaite, 2015, Determination of plasma heparin level improves identification of systemic mast cell activation disease, PLoS One, 10, e0124912, 10.1371/journal.pone.0124912 Sucker, 2008, Fatal bleeding due to a heparin-like anticoagulant in a 37-year-old woman suffering from systemic mastocytosis, Clin Appl Thromb Hemost, 14, 360, 10.1177/1076029607309173 Rosenberg, 1985, Role of heparin and heparinlike molecules in thrombosis and atherosclerosis, Fed Proc, 44, 404 Stack, 1994, Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase), J Biol Chem, 269, 9416, 10.1016/S0021-9258(17)36896-5 Rae Gross, 2017, Glycosaminoglycans inhibit substance P and IL-33-stimulated IL-8 and TNF release from human-cultured mast cells, FASEB J, 31, LB573 Welford, 2016, Serotonin biosynthesis as a predictive marker of serotonin pharmacodynamics and disease-induced dysregulation, Sci Rep, 6, 30059, 10.1038/srep30059 Kushnir-Sukhov, 2008, Clinical correlates of blood serotonin levels in patients with mastocytosis, Eur J Clin Invest, 38, 953, 10.1111/j.1365-2362.2008.02047.x Hanjra, 2018, Chromogranin A is not a biomarker of mastocytosis, J Allergy Clin Immunol Pract, 6, 687, 10.1016/j.jaip.2017.08.022 Maintz, 2011, Neuropeptide blood levels correlate with mast cell load in patients with mastocytosis, Allergy, 66, 862, 10.1111/j.1398-9995.2011.02550.x Kempuraj, 2004, Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells, Endocrinology, 145, 43, 10.1210/en.2003-0805 Theoharides, 2014, High serum corticotropin-releasing hormone (CRH) and bone marrow mast cell CRH receptor expression in a mastocytosis patient, J Allergy Clin Immunol, 134, 1197, 10.1016/j.jaci.2014.05.023 Kajiwara, 2010, Activation of human mast cells through the platelet-activating factor receptor, J Allergy Clin Immunol, 125, 1137, 10.1016/j.jaci.2010.01.056 Nilsson, 2000, Demonstration that platelet-activating factor is capable of activating mast cells and inducing a chemotactic response, Immunology, 99, 314, 10.1046/j.1365-2567.2000.00972.x Macpherson, 1989, Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis, Clin Exp Immunol, 77, 391 Guinot, 1988, Treatment of adult systemic mastocytosis with a PAF-acether antagonist BN52063, Lancet, 2, 114, 10.1016/S0140-6736(88)90055-4 Wong, 2009, Signalling mechanisms regulating the activation of human eosinophils by mast-cell-derived chymase: implications for mast cell-eosinophil interaction in allergic inflammation, Immunology, 126, 579, 10.1111/j.1365-2567.2008.02916.x Company, 2011, Contributions of ACE and mast cell chymase to endogenous angiotensin II generation and leucocyte recruitment in vivo, Cardiovasc Res, 92, 48, 10.1093/cvr/cvr147 Weidner, 1992, Mast-cell phenotype in indolent forms of mastocytosis. Ultrastructural features, fluorescence detection of avidin binding, and immunofluorescent determination of chymase, tryptase, and carboxypeptidase, Am J Pathol, 140, 847 de Paulis, 1999, Stem cell factor is localized in, released from, and cleaved by human mast cells, J Immunol, 163, 2799, 10.4049/jimmunol.163.5.2799 Dutta, 2011, Identification of novel target genes of nerve growth factor (NGF) in human mastocytoma cell line (HMC-1 (V560G c-Kit)) by transcriptome analysis, BMC Genomics, 12, 196, 10.1186/1471-2164-12-196 Peng, 2013, Increased circulating levels of neurotrophins and elevated expression of their high-affinity receptors on skin and gut mast cells in mastocytosis, Blood, 122, 1779, 10.1182/blood-2012-12-469882 McNeil, 2015, Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions, Nature, 519, 237, 10.1038/nature14022 Jennings, 2018, Patient perceptions in mast cell disorders, Immunol Allergy Clin North Am, 38, 505, 10.1016/j.iac.2018.04.006 Alvarez-Twose, 2014, Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM, J Allergy Clin Immunol, 133, 520, 10.1016/j.jaci.2013.06.020 Horan, 1990, Cromolyn sodium in the management of systemic mastocytosis, J Allergy Clin Immunol, 85, 852, 10.1016/0091-6749(90)90067-E Wong, 2000, Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema, J Allergy Clin Immunology, 105, 997, 10.1067/mai.2000.104571 Travis, 1988, Systemic mast cell disease. Analysis of 58 cases and literature review, Medicine, 67, 345, 10.1097/00005792-198811000-00001 van der Veer, 2014, Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis, J Allergy Clin Immunology, 134, 1413, 10.1016/j.jaci.2014.05.003 Kushnir-Sukhov, 2006, Elevated tryptase levels are associated with greater bone density in a cohort of patients with SM, Int Arch Allergy Immunol, 139, 265, 10.1159/000091172 Rossini, 2016, Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis, Osteoporosis Int, 27, 2411, 10.1007/s00198-016-3539-1 Yoshida, 2009, Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha, Intern Med, 48, 1973, 10.2169/internalmedicine.48.2294 Pieri, 2016, Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients, Am J Hematol, 91, 692, 10.1002/ajh.24382 Butterfield, 2005, Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long-term follow-up of a case, Leuk Res, 29, 131, 10.1016/j.leukres.2004.05.003 Hauswirth, 2004, Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature, Leuk Res, 28, 249, 10.1016/S0145-2126(03)00259-5 Laroche, 2011, Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis, Am J Med, 124, 776, 10.1016/j.amjmed.2011.02.038 Hughes, 2018, Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair®), Clin Exp Dermatol, 43, 573, 10.1111/ced.13408 Sokol, 2014, Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report, J Allergy Clin Immunol Pract, 2, 266, 10.1016/j.jaip.2014.03.009 Broesby-Olsen, 2018, Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations, Allergy, 73, 230, 10.1111/all.13237 Lieberoth, 2015, Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab, Case Rep Med, 2015, 903541, 10.1155/2015/903541 Castells, 2015, Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both?, J Allergy Clin Immunol Pract, 3, 350, 10.1016/j.jaip.2015.03.015 da Silva, 2013, Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome, J Allergy Clin Immunol Pract, 1, 687, 10.1016/j.jaip.2013.07.004 Chen, 2018, Mast cell disorders: protean manifestations and treatment responses, Ann Allergy Asthma Immunol, 121, 128, 10.1016/j.anai.2018.03.027 Jagdis, 2014, Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome, Ann Allergy Asthma Immunol, 113, 115, 10.1016/j.anai.2014.05.001 Tefferi, 2001, Treatment of systemic mast-cell disease with cladribine, N Engl J Med, 344, 307, 10.1056/NEJM200101253440415 Lim, 2009, Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine, Am J Hematol, 84, 790, 10.1002/ajh.21561 Barete, 2015, Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis, Blood, 126, 1009, 10.1182/blood-2014-12-614743 Akin, 2015, Cladribine for mastocytosis: benefits and risks, Blood, 126, 931, 10.1182/blood-2015-06-649525 Alstadhaug, 2017, Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine, J Clin Virol, 88, 17, 10.1016/j.jcv.2016.12.005 Vega-Ruiz, 2009, Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis, Leuk Res, 33, 1481, 10.1016/j.leukres.2008.12.020 Droogendijk, 2006, Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial, Cancer, 107, 345, 10.1002/cncr.21996 Pardanani, 2003, Imatinib for systemic mast-cell disease, Lancet, 362, 535, 10.1016/S0140-6736(03)14115-3 Musto, 2004, Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis, Leuk Res, 28, 421, 10.1016/j.leukres.2003.09.001 Gotlib, 2010, KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial, Blood, 116, 316, 10.1182/blood.V116.21.316.316 Jawhar, 2017, Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers, Blood, 130, 137, 10.1182/blood-2017-01-764423 Verstovsek, 2008, Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis, Clin Cancer Res, 14, 3906, 10.1158/1078-0432.CCR-08-0366 Purtill, 2008, Dasatinib therapy for systemic mastocytosis: four cases, Eur J Haematol, 80, 456, 10.1111/j.1600-0609.2008.01048.x DeAngelo, 2017, Clinical activity in a phase 1 study of Blu-285, a potent, highly-selective inhibitor of KIT D186V in advanced systemic mastocytosis (AdvSM), Blood, 130, 2